Skip to main content Skip to section navigation Skip to footer
Careers News & Media Contact
OPKO Health, Inc. OPKO Health, Inc.
  • Therapies
    • Overview
    • Ngenla
    • Rayaldee
  • Research
    • Overview
    • Pipeline
    • Publications
    • Scientific Presentations
  • Diagnostics
  • Company
    • Overview
    • Leadership
    • Locations
  • Partnerships
  • Investors
    • Overview
    • News / Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • News & Media
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Proxy Materials
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Form 8937
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 09, 2015 9:00am EDT

OPKO Health Announces Global License Agreement for the Discovery of Novel Antimicrobials

Sep 02, 2015 10:54am EDT

OPKO Licensee TESARO Receives FDA Approval for VARUBI™ (rolapitant)

Aug 26, 2015 9:11am EDT

OPKO Letter to Shareholders

Aug 25, 2015 1:00pm EDT

OPKO Health to Be Present at the Barrington Research Fall Investment Conference

Aug 20, 2015 10:42am EDT

OPKO Completes Acquisition of Bio-Reference Laboratories

Aug 19, 2015 12:19pm EDT

OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services Including the 4Kscore® Test

Aug 05, 2015 4:00pm EDT

OPKO Announces Second Quarter Operating and Financial Results

Aug 05, 2015 1:18pm EDT

Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE conference)

Jul 30, 2015 4:35pm EDT

OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015

Jul 28, 2015 1:41pm EDT

FDA Accepts OPKO’s New Drug Application for Rayaldee™

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • …
  • Page 52
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137


T: 305-575-4100
contact@opko.com

©2025 OPKO Health, Inc. All Rights Reserved.
Privacy Policy Governance Terms of use Sitemap